Teva attempts laquinimod rescue with two new indications
This article was originally published in Scrip
Executive Summary
Teva and partner Active Biotech have taken their troubled compound laquinimod into Phase II trials in two new settings; primary progressive multiple sclerosis (PPMS) and Huntington's disease. The move could be a way for Teva to rescue the drug's prospects, which were looking uncertain after rejection from European regulatory authorities earlier this year.